Sandra D’Angelo, Attending Physician at Memorial Sloan Kettering Cancer Center, shared a post by Clinical Cancer Research on X, adding:
“This study helps move sarcoma immunotherapy toward biomarker-driven precision care. By integrating circulating immune profiles, tumor microenvironment features, and digital pathology, we identify signals that may help predict who is most likely to benefit from ICB.”
Quoting Clinical Cancer Research on X:
“Now online: Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.”
Title: Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma Available to Purchase
Authors: Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, Martina Bradic, Jasme Lee, Mathew Adamow, Sujana Movva, Ciara M. Kelly, Viswatej Avutu, Lauren B. Banks, Jason E. Chan, Ping Chi, Mark A. Dickson, Mrinal M. Gounder, Mary L. Keohan, Robert G. Maki, Damon R. Reed, Paige Fuentes, Paige Collins, Rhoena Desir, Allison Reiner, Oleg Baranov, Konstantin Chernyshov, Nikita Kotlov, Ajay Subramanian, Everett J. Moding, Li-Xuan Qin, Phillip Wong, William D. Tap, Cristina R. Antonescu, Katherine S. Panageas, Ronglai Shen, Sandra P. D’Angelo
Other articles featuring Sandra D’Angelo on OncoDaily.